Publications by authors named "Marta Guzman"

Claim this Profile
D
Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts.
Andreu Òdena, Laia Monserrat, Fara Brasó-Maristany, Eduardo García-Galea, Eloi Casals

NPJ Precis Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer.
Fabio Giuntini, Íñigo González-Larreategui, Andrea Herencia-Ropero, Silvia Casacuberta-Serra, Mariano F Zacarías-Fluck, Marta Guzman

Cell Rep· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Breast Cancer.
Flaminia Pedretti, Mohmed Abdalfttah, Benedetta Pellegrino, Francesca Mateo, Paula Martínez-Sanz

Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the COVID-19 pandemic on the incidence of pediatric intracranial empyemas in Spain.
Marina Fidalgo de la Rosa, Gregorio Catalán Uribarrena, Pablo Martín Munarriz, Sara Iglesias Moroño, Marc Valera Melé

Childs Nerv Syst· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editor's Note: 4E-Binding Protein 1, a Cell Signaling Hallmark in Breast Cancer That Correlates with Pathologic Grade and Prognosis.
Federico Rojo, Laura Najera, José Lirola, José Jiménez, Marta Guzmán

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.
Andrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, Joanna Domènech-Vivó, Eduardo García-Galea

Genome Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer.
Laura Pascual-Reguant, Queralt Serra-Camprubí, Debayan Datta, Damiano Cianferoni, Savvas Kourtis, Marta Guzman

EMBO Mol Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER breast cancer.
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez

Nat Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Violeta Serra, Anderson T Wang, Marta Castroviejo-Bermejo, Urszula M Polanska, Marta Palafox, Marta Guzman

Clin Cancer Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER breast cancer.
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez

Nat Commun· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop-Guevara, Flaminia Pedretti, Alejandro Moles-Fernández

Cancer Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding.
Daniel Massó-Vallés, Marie-Eve Beaulieu, Toni Jauset, Fabio Giuntini, Mariano F Zacarías-Fluck, Marta Guzman

Cancer Res Commun· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer.
Mònica Sánchez-Guixé, Cinta Hierro, José Jiménez, Cristina Viaplana, Guillermo Villacampa

Clin Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
Albert Gris-Oliver, Yasir H Ibrahim, Martín A Rivas, Celina García-García, Mònica Sánchez-Guixé

Br J Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Albert Gris-Oliver, Marta Palafox, Laia Monserrat, Fara Brasó-Maristany, Andreu Òdena

Clin Cancer Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Marta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, Sara Gutiérrez-Enríquez, Mandy Ducy

EMBO Mol Med· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.
Azad Saei, Marta Palafox, Touati Benoukraf, Nishi Kumari, Patrick William Jaynes, Marta Guzman

J Exp Med· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Maria Teresa Herrera-Abreu, Marta Palafox, Uzma Asghar, Martín A Rivas, Rosalind J Cutts, Marta Guzman

Cancer Res· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
Celina García-García, Martín A Rivas, Yasir H Ibrahim, María Teresa Calvo, Albert Gris-Oliver

Clin Cancer Res· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.
Ana Bosch, Zhiqiang Li, Anna Bergamaschi, Haley Ellis, Eneda Toska, Marta Guzman

Sci Transl Med· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.
Yibing Yan, Violeta Serra, Ludmila Prudkin, Maurizio Scaltriti, Sumati Murli, Marta Guzman

Clin Cancer Res· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
Yasir H Ibrahim, Celina García-García, Violeta Serra, Lei He, Kristine Torres-Lockhart

Cancer Discov· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
Celina García-García, Yasir H Ibrahim, Violeta Serra, Maria Teresa Calvo, Marta Guzmán

Clin Cancer Res· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.
Maurizio Scaltriti, Violeta Serra, Emmanuel Normant, Marta Guzman, Olga Rodriguez

Mol Cancer Ther· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.
Maurizio Scaltriti, Pieter J Eichhorn, Javier Cortés, Ludmila Prudkin, Claudia Aura

Proc Natl Acad Sci U S A· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis